Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.

doi:10.1016/j.jtho.2020.12.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2021

Le Xiuning, Negrao Marcelo V, Reuben Alexandre, Federico Lorenzo, Diao Lixia, McGrail Daniel, Nilsson Monique, Robichaux Jacqulyne, Munoz Irene Guijarro, Patel Sonia, Elamin Yasir, Fan You-Hong, Lee Won-Chul, Parra Edwin, Solis Soto Luisa Maren, Chen Runzhe, Li Jun, Karpinets Tatiana, Khairullah Roohussaba, Kadara Humam, Behrens Carmen, Sepesi Boris, Wang Ruiping, Zhu Mingrui, Wang Linghua, Vaporciyan Ara, Roth Jack, Swisher Stephen, Haymaker Cara, Zhang Jianhua, Wang Jing, Wong Kwok-Kin, Byers Lauren A, Bernatchez Chantale, Zhang Jianjun, Wistuba Ignacio I, Gibbons Don L, Akbay Esra A, Heymach John V

Abstract excerpt

INTRODUCTION: Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated but remain incompletely understood. METHODS: We analyzed three cohorts of resected lung adenocarcinomas (Profiling of Resistance Patterns of Oncogenic Signaling Pathways in Evaluation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Adenosine

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mice

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33388477
DOI: 10.1016/j.jtho.2020.12.010
PMCID: PMC11160459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.PMID 33388477Read ↗

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.Semantic proximity Read ↗

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

The regulation of CD73 in non-small cell lung cancer.Semantic proximity Read ↗

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.Semantic proximity Read ↗

Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.Semantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.Semantic proximity Read ↗

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.Semantic proximity Read ↗

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read ↗

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.